Skip to main content

Table 1 Planned clinical trials of iPS cell-based therapies

From: iPS cell technologies: significance and applications to CNS regeneration and disease

Principal investigator (Institute/Location) Cell type to transplant Target disorders
Masayo Takahashi, (RIKEN) Retinal Pigment Epithelium (sheet) Age-related macular degeneration (wet type)
Alfred Lane, Anthony Oro, Marius Wernig (Stanford University) Keratinocytes Recessive dystrophic epidermolysis bullosa (RDEB)
Mahendra Rao (NIH) DA neurons Parkinson’s disease
Koji Eto (Kyoto University) Megakaryocyte Thrombocytopenia
Jun Takahashi (Kyoto University) DA neurons Parkinson’s disease
Steve Goldman, (University of Rochester) Oligodendrocyte precursor cell Multiple Sclerosis
Hideyuki Okano, Masaya Nakamura (Keio University) Neural stem/progenitor cells Spinal Cord Injury
Shigeto Shimmura (Keio University) Corneal endothelial cells Corneal endothelial dysfunction
Koji Nishida (Osaka University) Corneal epithelial cells (sheet) Corneal epithelial dysfunction and trauma (e.g. Stevens–Johnson syndrome)
Yoshiki Sawa (Osaka University) Cardiomyocytes (sheet) Heart Failure
Keiichi Fukuda (Keio University) Cardiomyocytes (sphere) Heart Failure
Yoshiki Sasai and Masayo Takahashi (RIKEN) Neuroretinal sheet including photoreceptor cells Retinitis pigmentosa
Advanced Cell Technology Megakaryocytes Refractory thrombocytopenia
  1. Representative studies of iPS-based cell therapy with planned clinical trials are listed.
  2. References: [17, 1929].